A New Molecularly Targeted Therapeutic for Breast Cancer
The FDA approved a molecularly targeted therapy for treating patients with a certain form of breast cancer.
Progress Against Cancer
The FDA approved a molecularly targeted therapy for treating patients with a certain form of breast cancer.
The FDA expanded an immunotherapeutic to used for treating patients with hepatocellular carcinoma – the most common form of primary liver cancer.
The FDA expanded the use of an immunotherapeutic to include the treatment of certain patients with stomach cancer (gastric cancer).
The FDA approved a molecularly targeted therapy for treating certain adults with follicular lymphoma, a form of non-Hodgkin lymphoma.
The FDA has approved a CD22-targeted antibody-drug conjugate for treating certain adults with ALL. The U.S. Food and Drug Administration (FDA) recentlyapproved a new molecularly targeted therapeutic called inotuzumab ozogamicin (Besponsa) for treating certain...
Treatment approved for the treatment of adults with two types of acute myeloid leukemia that have particularly poor prognoses.
Enasidenib is the second molecularly targeted therapeutic approved by the FDA for treating AML in recent months. The U.S. Food and Drug Administration (FDA) recentlyapproved the molecularly targeted therapeutic enasidenib (Idhifa) for treating certain...
The FDA expanded the use of the immunotherapy nivolumab to include the treatment of certain patients with colorectal cancer.
The FDA approved the first of a new class of immunotherapy known as CAR T-cell therapy for treating patients with acute lymphoblastic leukemia.
Study: Women with periodontal disease had higher risk of several cancer types, including breast cancer, esophageal cancer, and oral cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More